Role of depression, anxiety, testosterone and luteinizing hormone levels in disorders of sexual function

Nagendar Reddy Jakka¹*, Jayanthy Ramesh²

¹Assistant Professor, Department of Endocrinology, Kamineni Academy of Medical Sciences and Research Center, L. B. Nagar, Hyderabad, Telangana, India
²Professor, Department of Endocrinology, Andhra Medical College, Vishakhapatnam, Andhra Pradesh, India

Received: 31 May 2017
Accepted: 27 June 2017

*Correspondence:
Dr. Nagendar Reddy Jakka,
E-mail: nagenderj1979@gmail.com

ABSTRACT

Background: Hypogonadism as well as deficiency of testosterone can lead to disorder of sexual function in males. The initial clinical manifestations of this are mostly erectile dysfunction (ED) and hypoactive sexual desire disorder (HSSD). This not only causes the sexual dysfunction but can also lead to many health problems. To study the role of depression, anxiety, testosterone and luteinizing hormone levels in disorders of sexual function

Methods: A hospital based cross sectional study was conducted at department of General Medicine, Kamineni Academy of Medical Sciences, Hyderabad for a period of one year among 60 eligible study subjects to study the role of depression, anxiety, testosterone and luteinizing hormone levels in disorders of sexual function. All male patients aged between 21-60 years, who had stable heterosexual relationship, were included. Patients with severe diseases, users of alcohol and smoking, having marital disharmony were excluded. Informed consent was obtained from all the patients.

Results: Testosterone and LH levels are significantly lower in subjects with SD, suggesting that a state of hypogonadotropic hypogonadism prevails in male diabetics with SD. Depression and anxiety are significant factors associated with SD. Premature Ejaculation is significantly associated with Anxiety.

Conclusions: Testosterone and LH levels are significantly lower in subjects with SD. Depression and anxiety is significant factors associated with SD. Premature Ejaculation is significantly associated with anxiety.

Keywords: Luteinizing hormone, Metabolic disorder, Testosterone

INTRODUCTION

Hypogonadism as well as deficiency of testosterone can lead to disorder of sexual function in males. The initial clinical manifestations of this are mostly erectile dysfunction (ED) and hypoactive sexual desire disorder (HSSD). This not only causes the sexual dysfunction but can also lead to many health problems.¹ Many studies may be required to prove the fact that therapy with testosterone can improve the sexual function, and quality of life of males.² It was found by one author that psychological factors were responsible for 50% of cases of ED and were found to be as an independent risk factor of ED.³

Depression is characterized by loss of interest, reduction in energy, lowered self-esteem and inability to experience pleasure: irritability and social withdrawal may impair the ability to form and maintain intimate relationships. Depressive symptoms produce difficulty in sexual relationship. In some patients, low sexual desire may land them into depression.⁴
Anxiety can be defined as a feeling of apprehension and fear characterized by physical, psychological, and cognitive symptoms. In the context of stress or danger, these reactions are normal. However, some people feel extremely anxious with everyday activities, which may result in distress and significant impairment of normal activity. Various aspects of anxiety are historically considered in arousal disorders, particularly the vicious circle of anxiety-SD-performance anxiety.  

Diabetic men show decreased libido. But to prove the fact, very few studies are available. In two studies, the existence of an inverse relationship between age and sexual interest was found.  

HSDD is probably the most difficult to evaluate SD. Several reliable and valid questionnaires are available for assessing sexual desire problems. Once HSDD has been established, mood disorders like depression, anxiety and psychotic disorders, drugs’ side effect and relationship problems should be ruled out. In men with acquired HSDD, once all of these potential etiologies have been discarded, blood test, including testosterone, should be performed.  

There are no studies focusing on DE in patients of diabetes as a risk factor. AE can be due to lack of peristalsis of the vas. AE is caused by diabetic autonomic neuropathy. If there is a problem in the internal sphincter of bladder, then it can lead to retrograde ejaculation (RE).  

Hence present study was carried out to study the role of depression, anxiety, testosterone and luteinizing hormone levels in disorders of sexual function.  

**METHODS**

A hospital based cross sectional study was conducted at Department of General Medicine, Kamineni Academy of Medical Sciences, Hyderabad for a period of one year among 60 eligible study subjects to study the role of depression, anxiety, testosterone and luteinizing hormone levels in the disorders of sexual function. All male patients aged between 21-60 years, who had stable heterosexual relationship, were included. Patients with severe diseases, users of alcohol and smoking, having marital disharmony were excluded. Informed consent was obtained from all the patients. Institutional Ethics Committee permission was taken.  

Detailed History and clinical examination was carried out for each and every individual. Body mass index (BMI) was calculated by dividing weight (kg) by the height squared (m²). Waist circumference (to the nearest centimeter) was measured with measuring tape at midway between the iliac crest and the costal margin (lower rib). Blood pressure was recorded in standing and supine positions.  

**Testosterone**

Serum total testosterone was estimated by CLIA method. For patients aged 20-49 years, the median lab reference range for testosterone was 6.2 ng/ml and the absolute reading was 2.7-17.3 ng/ml. For patients aged more than 50 years, the median lab reference range for testosterone was 4.3 ng/ml and the absolute reading was 2.1-7.5 ng/ml.  

**Luteinizing hormone levels**

Serum luteinizing hormone levels were estimated by CLIA method. Lab reference range was 3.9-22.6 mIU/ml.  

Generalized Anxiety Disorder Screener was used for evaluation of Anxiety Disorder. Patients were evaluated for depression by administering the nine item Patient Health Questionnaire translated version questionnaire. The score of 5-9 was mild depression, score of 10-14 was moderate depression, score of 15-19 was moderately severe depression and score of 20 or more was severe depression.

Premature ejaculation (PE) diagnostic tool: It was interpreted as follows

| Score | Interpretation |
|-------|----------------|
| ≥ 11  | Diagnosis of PE confirmed |
| 9-10  | Borderline PE |
| 8 or less | Not having PE |

**Specimen collection**

Samples were taken between 8:00 and 9:00 AM in fasting state for hormonal estimation and lipid profile. 8 ml of venous blood sample was collected. Two serum tubes were used for 4 ml blood sample. Of this, 2 ml was taken into EDTA tube to investigate HbA1c, remaining 2 ml was collected for measuring fasting plasma glucose into sodium fluoride tubes. First centrifuged and then immediately frozen at -20°C pending further analysis. PPG was estimated in the sample collected 2 hours after the beginning of food intake. Lipid profile was estimated in fresh sera. The remaining serum was used to estimate the hormones and creatinine. All assays were performed within 2 days of collecting the sample. Grossly hemolysed and lipemic were excluded.

**Statistical analysis**

Data was entered in Microsoft Excel worksheet and analyzed using proportions. Statistical tests like chi square test was used and a p value of less than 0.05 was taken as statistically significant.
RESULTS

Table 2 shows association of depression with sexual dysfunction. It was found that the prevalence of sexual dysfunction was 88.8% among patients with depression compared to 54.5% among those with no depression. This difference was found to be statistically significant.

Table 2: Association of depression with sexual dysfunction.

| Depression | Sexual dysfunction | Total | Chi square | P value |
|------------|--------------------|-------|------------|---------|
| Yes        | Yes                | 24    | 0.004      | Significant |
|            | No                 | 03    |            |          |
| No         | Yes                | 18    |            |          |
|            | No                 | 15    |            |          |
| Total      |                    | 42    | 6.785      |          |

Table 3 shows association of anxiety with sexual dysfunction. It was found that the prevalence of sexual dysfunction was 100% among patients with anxiety compared to 64% among those with no anxiety. This difference was found to be statistically significant.

Table 3: Association of anxiety with sexual dysfunction.

| Anxiety | Sexual dysfunction | Total | Chi square | P value |
|---------|--------------------|-------|------------|---------|
| Yes     | Yes                | 10    | 0.023      | Significant |
|         | No                 | 00    |            |          |
| No      | Yes                | 32    |            |          |
|         | No                 | 18    |            |          |
| Total   |                    | 42    | 5.143      |          |

Figure 1 shows association between LH level and sexual dysfunction. LH level (p = 0.001) was significantly higher in SD group.

Figure 2 shows association between testosterone level and sexual dysfunction. Testosterone level (347.89 ±147.899 vs 455.52 ±168.177; p=0.016) was significantly higher in SD group.

DISCUSSION

Depression is significantly associated with sexual dysfunction (p = 0.044) in our study. Similar findings were observed Casper et al, Mathew et al, and Angst et al.9-11 In all these studies, the respective authors have found that among patients with depression, the prevalence of sexual dysfunction was very high. They concluded this observation for all types of depression including recurrent brief depression, dysthymia and major depression. The prevalence of sexual dysfunction was twice among patients with depression than the patients without depression.12

Anxiety disorder is significantly associated with sexual dysfunction (p=0.023) in our present study. Kaplan et al also suggest that anxiety disorder is associated with SD in men.13 It has been an accepted fact that anxiety leads to disorders of sexual arousal. There is a vicious circle of anxiety leading to sexual dysfunction and sexual dysfunction leading to performance anxiety.14

Shamloul has observed that honeymoon impotence was a citing example of this condition.15 Among males suffering from ED, are usually found to have a 2.5% to 37% prevalence of disorders of anxiety.16 Anxiety (P= 0.0043) is significantly associated with PE in our study. Dunn KM et al, study suggests that anxiety is associated with PE.17 Surprisingly PE was not correlated with metabolic, hormonal and complication status in type 2 DM in this study.

It is a well-known fact that androgens play an important role as a regulator of sexual behavior especially in males.18 We found that among males diagnosed as having sexual disorder, the mean levels of testosterone were highly significantly lower than their counterparts who had no sexual dysfunction. (347.89±22.821 versus 455.52±39.640 ng/dl; p = 0.016). These findings are similar to the findings and observations of a study done previously.19 It was postulated that high levels of testosterone can reduce the erection latency provided that
erection was due to stimulation of sexual material. It was also found that substitution of testosterone especially in males with hypogonadism, arouses the interest in sex, leads to decreased latency and at the same time had positive effect on nocturnal penile tumescence (NPT). Grossmann et al noted that a very high number of diabetic males had deficiency of testosterone and they were found to have symptoms of hypogonadism. Thus, in males with type 2 diabetes mellitus, as their symptoms are not very specific, it is difficult to diagnose hypogonadism.

In males with type 2 diabetes mellitus, for diagnosis of borderline hypogonadism, it is important to measure the bioavailability of testosterone. In a study, it was found that incidence of free available testosterone concentration was 44% and 33% in diabetic and non-diabetic men respectively.

LH level ($p = 0.001$) was significantly lower in SD group in our study. These findings of significantly low LH and testosterone levels in SD group suggest that a state of functional hypogonadism prevails in this group. The association between type 2 diabetes mellitus and hypogonadotropic hypogonadism was proved in some studies. The incidence of hypogonadotropic hypogonadism was found to be ranging from 25% to 40% in males with type 2 diabetes mellitus. In younger males aged 18 to 35 years with diabetes also, it was observed that the prevalence of hypogonadotropic hypogonadism was at an alarming high rate of 33%.

Males with type 2 diabetes mellitus having low levels of testosterone have high prevalence of hypogonadism. They suffer from erectile dysfunction and easy fatigue. The prevalence of hypogonadotropic hypogonadism is rare in patients with type 1 diabetes mellitus. So, there is confusion over the role of hyperglycemia in hypogonadotropic hypogonadism. Also we know that as the body mass index increases, the testosterone levels decrease. This is applicable for both type 1 and type 2 forms of diabetes mellitus. Hence some consider that hypogonadotropic hypogonadism may be due to insulin resistance. Studies related to hypogonadism speak about insulin resistance, metabolic syndrome and central obesity as the prominent risk factors for hypogonadism. In view of all these observations, the Endocrine Society recommends that men with low testosterone and symptoms of androgen deficiency be considered for therapy with testosterone.

CONCLUSION

Testosterone and LH levels are significantly lower in subjects with SD. Depression and anxiety are significant factors associated with SD. Premature Ejaculation is significantly associated with Anxiety. We conclude that any diabetic patient presented with PE should be focused on management of anxiety.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the institutional ethics committee

REFERENCES

1. Buvent J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, et al. Endocrine aspects of male sexual dysfunctions. J Sexual Med. 2010;7(4pt2):1627-56.
2. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Type 2 diabetes mellitus and testosterone: A meta-analysis study. Int J Androl. 2011;34(6pt1):528-40.
3. Veves A, Webster L, Chen TF, Payne S, Boulton AJ. Aetiology of sexual dysfunction and management of impotence in diabetic males: four years experience from a combined clinic. Diabetic Med. 1995;12(1):77-82.
4. Baldwin DS. Depression and sexual function. J Psychopharmacol. 1996;10(Suppl 1):S30-4.
5. Sugimori H, Yoshida K, Tanaka T, Baba K, Nishida T, Nakazawa R, et al. PSYCHOLOGY: Relationships between Erectile Dysfunction, Depression, and Anxiety in Japanese Subjects. J Sexual Med. 2005;2(3):390-6.
6. Malavige LS, Jayaratne SD, Kathiriarchchi ST, Sivayogam S, Fernando DJ, Levy JC. Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. The J Sexual Med. 2008;5(9):2125-34.
7. Segraves RT. Management of hypoactive sexual desire disorder. Adv Psychosom Med. 2008;29:23-32.
8. Sexton WJ, Jarow JP. Effect of diabetes mellitus upon male reproductive function. Urol. 1997;49:508-13.
9. Casper RC, Redmond DE, Katz MM, Schaffer CB, Davis JM, Koslow SH. Somatic symptoms in primary affective disorder: presence and relationship to the classification of depression. Archives General Psych. 1985;42(11):1098-104.
10. Mathew RJ, Weinman ML. Sexual dysfunctions in depression. Arch Sex Behav. 1982;11:323-5.
11. Angst J. Sexual problems in healthy and depressed patients. Int Clin Psychopharmacol. 1998;13(Suppl6):S1-3.
12. Baldwin DS. Depression and sexual function. J Psychopharmacol. 1996;10(Suppl 1):S30-4.
13. Kaplan HS. Anxiety and sexual dysfunction. J Clin Psych. 1988;49:21-5.
14. Masters WH, Johnson VE. Human Sexual Inadequacy. Boston: Little Brown and Co; 1970.
15. Shamloul R. Management of honeymoon impotence. J Sex Med. 2006;3:361-366.
16. Mallis D, Moysidis K, Nakopoulou E, Papahritou S, Hatzimouratidis K, Hatzichristou D. Psychiatric morbidity is frequently undetected in patients with erectile dysfunction. J Urol. 2005;174(5):1913-6.
17. Dunn KM, Croft PR, Hackett GI. Association of sexual problem with social, psychological, and physical problems in men and women: a cross sectional population survey. J Epidemiol Community Health. 1999;53:144-8.
18. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev. 1987;8(1):1-28.
19. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002;25(1):55-60.
20. Lange JD, Brown WA, Wincze JP, Zwick W. Serum testosterone concentration and penile tumescence changes in men. Hormones and Behavior. 1980;14(3):267-70.
21. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab. 1983;57(3):557-62.
22. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, MacIsaac RJ, Clarke S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93(5):1834-40.
23. Dhindsa S, Miller MG, McWhirter CL, Mager DE, Ghanim H, Chaudhuri A, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes care. 2010;33(6):1186-92.
24. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Diabetes care. 2007;30(4):911-7.
25. Chandel A, Dhindsa S, Topiwala S, Chaudhuri A, Dandona P. Testosterone concentration in young patients with diabetes. Diabetes Care. 2008;31:2013-17.
26. Tomar R, Dhindsa S, Chaudhuri A, Mohanty P, Garg R, Dandona P. Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes care. 2006;29(5):1120-2.
27. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, MacIsaac RJ, Clarke S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93(5):1834-40.
28. Haffner SM. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord. 2008;24(Suppl 2):S56-S58.
29. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2006;91:1995-2010.

Cite this article as: Jakka NR, Ramesh J. Role of depression, anxiety, testosterone and luteinizing hormone levels in disorders of sexual function. Int J Adv Med 2017;4:1106-10.